Taj Pharmaceuticals – Premier Manufacturer & Supplier of Moxonidine Tablets BP 0.3mg in India

Taj Pharmaceuticals Ltd, a reputed name in the global pharmaceutical industry, proudly stands as a leading manufacturer, exporter, and supplier of Moxonidine Tablets BP 0.3mg from Vapi, Gujarat, India. With unmatched commitment to quality, compliance, and therapeutic efficacy, Taj Pharmaceuticals ensures that its Moxonidine Tablets BP meet the highest international standards.

Moxonidine, a potent antihypertensive agent, is widely prescribed for the treatment of high blood pressure (hypertension). Our formulation of Moxonidine Tablets BP 0.3mg (marketed under the name “Bimbo” in select regions) is a clinically trusted solution for improving cardiovascular health by easing arterial resistance and enhancing heart function.


What Is Moxonidine Tablets BP 0.3mg and Why It’s Prescribed

Moxonidine is an imidazoline receptor agonist, designed specifically to lower elevated blood pressure. It reduces sympathetic nerve activity, leading to vasodilation (relaxation of blood vessels), which eases the workload on the heart and reduces the risk of serious cardiovascular events such as:

  • Heart attack
  • Stroke
  • Kidney failure
  • Aneurysms

Moxonidine BP 0.3mg is especially effective in patients with metabolic syndrome, obesity, or diabetes, offering a better tolerability profile than older antihypertensives.


Taj Pharmaceuticals – Trusted Global Supplier of Moxonidine Tablets BP

At Taj Pharmaceuticals Ltd, we specialize in the bulk manufacturing and custom formulation of Finished Dosage Forms (FDFs), including Moxonidine Tablets BP 0.3mg. With our state-of-the-art WHO-GMP and EU-GMP compliant facilities, we cater to clients across:

  • India (PAN India supply)
  • Africa
  • Middle East
  • LATAM (Latin America)
  • CIS countries
  • South East Asia

As an export-focused manufacturer, we ensure regulatory documentation support, including COAs, MOA, COPPs, FSCs, and Stability Data to meet stringent registration requirements worldwide.


Pharmaceutical Strength & Composition

  • Product Name: Moxonidine Tablets BP 0.3mg
  • Generic Name: Moxonidine
  • Brand Name: Bimbo (in licensed markets)
  • Strength: 0.3 mg
  • Dosage Form: Tablet
  • Route of Administration: Oral
  • Therapeutic Class: Anti-Hypertensive
  • Packaging: 10 x 10 Tablets in Alu-Alu / Blister packs
  • Storage Condition: Store below 30°C, protect from light and moisture
  • Shelf Life: 36 months
  • Regulatory Status: Compliant with IP/BP/USP standards

Therapeutic Uses of Moxonidine Tablets BP

  • Treatment of primary hypertension
  • Secondary hypertension management
  • Ideal for hypertensive patients with insulin resistance
  • Adjunct therapy in metabolic cardiovascular syndrome
  • Suitable for patients intolerant to ACE inhibitors or beta-blockers

How Moxonidine Works in the Body

Moxonidine acts on the imidazoline receptors (I1) in the brainstem, reducing sympathetic outflow to the heart and blood vessels. This leads to:

  • Decreased heart rate
  • Reduced arterial resistance
  • Improved cardiac output
  • Lower systemic blood pressure

The selectivity for imidazoline receptors over alpha-2 adrenergic receptors results in fewer central side effects like sedation or dry mouth, making it a safer and more tolerable option.


Dosage & Administration Guidelines

  • Typical adult dose: 0.2 mg to 0.4 mg per day
  • Maximum dose: 0.6 mg/day in divided doses
  • Administration: Taken with or without food, preferably at the same time each day

Note: Always follow physician’s instructions. Dose adjustments are necessary for patients with renal impairment.

Side Effects & Precautions

While Moxonidine is well tolerated, some patients may experience:

  • Dry mouth
  • Headache
  • Dizziness
  • Fatigue or weakness
  • Nausea
  • Sleep disturbances

Precautions

  • Avoid sudden withdrawal to prevent rebound hypertension
  • Not recommended during pregnancy unless clearly needed
  • Monitor in elderly and renal-compromised patients
  • Avoid alcohol and CNS depressants

Why Choose Taj Pharmaceuticals for Moxonidine BP Tablets

✔️ WHO-GMP certified facilities with global compliance
✔️ 100% Batch Traceability & Validation
✔️ High-purity API sourcing and in-house R&D formulation
✔️ Strict adherence to BP, IP & USP standards
✔️ Customized packaging & private labeling
✔️ Comprehensive technical & regulatory support
✔️ PCD Pharma Franchise Opportunities available PAN India


Moxonidine Tablets PCD Franchise & Export Business

Taj Pharmaceuticals invites pharma distributors, PCD franchise partners, government tenders, and hospital procurement heads to collaborate on Moxonidine Tablets BP 0.3mg. We provide:

  • Promotional support & marketing materials
  • Third-party manufacturing under your brand
  • Fast dispatch timelines
  • Affordable pricing with top-notch quality

Availability Across India & Globally

We ensure seamless PAN India delivery of Moxonidine Tablets 0.3mg, especially in:

  • Mumbai, Maharashtra
  • Delhi NCR
  • Bangalore, Karnataka
  • Chennai, Tamil Nadu
  • Ahmedabad, Gujarat

And actively export to:

  • GCC countries (UAE, Oman, Saudi Arabia)
  • African nations (Nigeria, Kenya, Tanzania)
  • Latin America (Mexico, Brazil, Peru)
  • CIS & Central Asia (Russia, Kazakhstan)

Connect With Taj Pharmaceuticals for Bulk Orders

If you’re looking for a reliable Moxonidine Tablets BP 0.3mg manufacturer in India, reach out to Taj Pharmaceuticals – the brand trusted globally for its affordability, compliance, and therapeutic value.

📧 Email: info@tajpharma.com
🌐 Website: www.tajpharma.com
📞 Call/WhatsApp: +91 84484 44095
☎️ Landline: +91-22-2637 4592 / 2637 4593


Taj Pharmaceuticals is the No.1 manufacturer and exporter of Moxonidine Tablets BP 0.3mg in India, offering premium quality medicines with global reach. From hospital supply chains to government procurement and PCD partnerships, we provide tailor-made solutions to meet every pharmaceutical requirement. Our commitment to quality, regulatory support, and affordability sets us apart in the highly competitive generic medicine market.